Table 2 Clinical characteristics
Total n = 336 | Delta dominance n = 141 | Omicron dominance n = 195 | p -value | p -value* | |
|---|---|---|---|---|---|
SpO2 < 95% | 48 (14.29) | 25 (17.73) | 23 (11.79) | 0.1 | 1.0 |
Fever | 216 (64.29) | 89 (63.12) | 127 (65.13) | 0.7 | 1.0 |
Shortness of breath | 28 (8.33) | 13 (9.22) | 15 (7.69) | 0.7 | 1.0 |
Rapid breathing | 3 (0.89) | 2 (1.42) | 1 (0.51) | 0.7 | 1.0 |
Cough | 213 (63.39) | 82 (58.16) | 131 (67.18) | 0.1 | 1.0 |
Runny nose | 118 (35.12) | 59 (41.84) | 59 (30.26) | 0.03 | 0.42 |
Sore throat | 195 (58.04) | 72 (51.06) | 123 (63.08) | 0.03 | 0.42 |
Loss of smell or taste | 110 (32.74) | 88 (62.41) | 22 (11.28) | < 0.0001 | < 0.0001 |
Chest pain | 7 (2.08) | 3 (2.13) | 4 (2.05) | 1.0 | 1.0 |
Reduced exercise capacity | 8 (2.38) | 3 (2.13) | 5 (2.56) | 1.0 | 1.0 |
Myoclonus | 2 (0.60) | 1 (0.71) | 1 (0.51) | 1.0 | 1.0 |
Decreased appetite | 46 (13.69) | 30 (21.28) | 16 (8.21) | 0.001 | 0.014 |
Vomiting | 3 (8.93) | 2 (1.42) | 1 (0.51) | 0.7 | 1.0 |
Duration of treatment (days) | 8 (7—11) | 10 (7—14) | 7 (6—10) | < 0.0001 | < 0.001 |